ScreenerHero

GNPX Genprex, Inc.

NAS · US · Healthcare · Biotechnology · genprex.com
2.620USD+0.38%Mkt Cap: 2.15M $P/E: —

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new the…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.15M USD
Enterprise Value-13.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-16.23M USD
Revenue/Share—
Last Price2.620 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.20
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.09
EPS (TTM)-8.99
EPS (Forward)-2.18
52W Range
0.42294% of range55.00
52W High55.00 USD
52W Low0.4229 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-203.83%
ROA-159.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.31M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-492.41%
Net Debt-15.15M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio6.76
Quick Ratio6.47
Book Value/Sh29.23 USD
Cash/Share18.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:22
Split DateJul 16, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.819.71K
Float818.72K
Insiders0.21%
Institutions1.73%
Short Interest
Short Ratio0.3d
Short % Float10.11%
Short % Out.10.09%
Shares Short82.75K
Short (prev mo.)62.59K
Technical
SMA 504.039 (-35.1%)
SMA 20024.49 (-89.3%)
Beta-0.97
S&P 52W Chg16.45%
Avg Vol (30d)187.72K
Avg Vol (10d)421.72K
Technical Indicators
RSI (14)34.7
MACD-0.3482
MACD Signal-0.3078
MACD Hist.-0.0404
BB Upper3.944 USD
BB Middle3.159 USD
BB Lower2.374 USD
BB Width49.69%
ATR (14)0.3281 USD
Vol Ratio (20d)0.82x